This submission follows the positive results of the CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity) Programme, first presented at the European Society of Cardiology (ESC) in August 2003. CHARM proved Atacand, as the first AT1-receptor blocker, to reduce both cardiovascular deaths as well as hospital admissions, across a broad spectrum of patients with chronic heart failure1.
Additional analyses of the CHARM data, presented at the ACC (American College of Cardiology Meeting, New Orleans, 7-10 March), added further evidence for the benefits of Atacand in CHF. One analysis2 found that New York Heart Association (NYHA) functional class improved in a broad spectrum of CHF patients treated with Atacand.
Commenting on the heart failure submission for Atacand, Gunnar Olsson, VP and Head of the Cardiovascular Therapy Area said: "Heart failure remains a very serious, costly condition and there is still a real need for additional, effective therapies. It is a major cause of death, hospital admissions and self-reported quality of life is impaired more by CHF than by any other common chronic medical disorder3,4." He continued: "AstraZeneca is delighted that CHARM has shown that Atacand can benefit a broad range of heart failure patients. This file submission is a step further towards Atacand becoming available to doctors as a new and effective treatment option, offering more benefits to patients both in terms of better outcomes, including improved symptom co
Contact: Elizabeth Rickard